Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balovaptan in pediatric ASD (aV1ation)
NCT02901431Phase 2Terminated
- Sponsor
- Roche
- Start
- Nov 2016
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of balovaptan in Autism Spectrum Disorder (ASD) (3 arms), sponsored by Roche. Primary endpoint: Vineland-II Adaptive Behavior Scale Two Domain Composite Score at 24 weeks. Started Nov 2016; status: terminated.
02
Drugs
balovaptan
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02901431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02901431.